ProJenX, Inc. Names Stan E. Abel as CEO
Stan E. Abel has been named Chief Executive Officer of ProJenX Inc. He joins the company following its recent launch by Medical Excellence Capital in collaboration with Project ALS, a leading nonprofit organization dedicated to ALS research, and renowned Columbia University researchers. Stan was the CEO of SiteOne Therapeutics Inc. before joining ProJenX, where he led a team developing new treatments for acute and chronic pain.
ProJenX is a biopharmaceutical company that develops novel small molecule therapeutics that target motor neuron degenerative pathways.
ProJenX closed its last funding round on Jan 21, 2022, from a Seed round.